Iovance Biotherapeutics (IOVA) Competitors $2.05 -0.15 (-6.82%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.03 (+1.66%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. APLS, CRNX, KYMR, TLX, AMRX, RARE, SRRK, XENE, VKTX, and MORShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Apellis Pharmaceuticals (APLS), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Telix Pharmaceuticals (TLX), Amneal Pharmaceuticals (AMRX), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Apellis Pharmaceuticals Crinetics Pharmaceuticals Kymera Therapeutics Telix Pharmaceuticals Amneal Pharmaceuticals Ultragenyx Pharmaceutical Scholar Rock Xenon Pharmaceuticals Viking Therapeutics MorphoSys Apellis Pharmaceuticals (NASDAQ:APLS) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has stronger valuation and earnings, APLS or IOVA? Apellis Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$754.65M3.85-$197.88M-$1.82-12.64Iovance Biotherapeutics$164.07M4.52-$372.18M-$1.23-1.67 Do analysts recommend APLS or IOVA? Apellis Pharmaceuticals currently has a consensus target price of $34.12, suggesting a potential upside of 48.27%. Iovance Biotherapeutics has a consensus target price of $11.90, suggesting a potential upside of 480.49%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36 Is APLS or IOVA more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Iovance Biotherapeutics' net margin of -161.44%. Iovance Biotherapeutics' return on equity of -52.87% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% Iovance Biotherapeutics -161.44%-52.87%-41.31% Does the media prefer APLS or IOVA? In the previous week, Apellis Pharmaceuticals had 12 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 14 mentions for Apellis Pharmaceuticals and 2 mentions for Iovance Biotherapeutics. Apellis Pharmaceuticals' average media sentiment score of 0.30 beat Iovance Biotherapeutics' score of 0.22 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of APLS or IOVA? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, APLS or IOVA? Apellis Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. SummaryApellis Pharmaceuticals beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$741.79M$3.13B$5.76B$10.41BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-1.6720.5976.5226.72Price / Sales4.52385.20496.69161.98Price / CashN/A45.3237.1760.63Price / Book0.889.6513.716.39Net Income-$372.18M-$53.02M$3.29B$271.62M7 Day Performance-9.69%1.03%0.92%2.76%1 Month Performance-21.15%7.85%6.19%9.54%1 Year Performance-80.19%10.32%81.04%31.52% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.3109 of 5 stars$2.05-6.8%$11.90+480.5%-78.4%$741.79M$164.07M-1.67500APLSApellis Pharmaceuticals4.1474 of 5 stars$26.93-4.3%$34.12+26.7%-34.4%$3.40B$781.37M-14.80770Trending NewsInsider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.6662 of 5 stars$35.14-1.3%$68.86+96.0%-32.8%$3.31B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics2.0925 of 5 stars$43.26-0.6%$58.76+35.8%+10.2%$3.09B$47.07M-12.47170Trending NewsAnalyst ForecastInsider TradeTLXTelix Pharmaceuticals3.8241 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.06B$637.77M0.00N/AAnalyst ForecastGap UpHigh Trading VolumeAMRXAmneal Pharmaceuticals3.3773 of 5 stars$9.73+1.1%$11.60+19.2%+12.6%$3.06B$2.79B973.978,100Positive NewsAnalyst ForecastRAREUltragenyx Pharmaceutical4.3242 of 5 stars$31.51-1.0%$81.50+158.6%-49.5%$3.04B$560.23M-5.701,294SRRKScholar Rock4.3533 of 5 stars$31.52+0.4%$45.75+45.1%+292.7%$3.03B$33.19M-10.83140News CoverageAnalyst ForecastInsider TradeAnalyst RevisionXENEXenon Pharmaceuticals2.4065 of 5 stars$38.19-2.6%$53.30+39.6%-5.8%$2.94B$9.43M-10.76210Positive NewsOptions VolumeVKTXViking Therapeutics4.2873 of 5 stars$25.48-5.6%$86.92+241.1%-59.6%$2.86BN/A-16.6520Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Kymera Therapeutics Competitors Telix Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Scholar Rock Competitors Xenon Pharmaceuticals Competitors Viking Therapeutics Competitors MorphoSys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts